Cel Sci (CVM) EBIT (QoQ) (2010 - 2026)
Cel Sci (CVM) EBIT (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - |
| 10 | Cel Sci | 2.18 Mn | -4.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.80% |
| Dec 31, 2025 | 11.01% |
| Sep 30, 2025 | -9.92% |
| Jun 30, 2025 | 14.16% |
| Mar 31, 2025 | 7.24% |
| Dec 31, 2024 | -12.63% |
| Sep 30, 2024 | 8.24% |
| Jun 30, 2024 | 5.73% |
| Mar 31, 2024 | -9.10% |
| Dec 31, 2023 | 13.15% |
| Sep 30, 2023 | 8.73% |
| Jun 30, 2023 | -0.07% |
| Mar 31, 2023 | -6.87% |
| Dec 31, 2022 | 14.50% |
| Sep 30, 2022 | -2.62% |
| Jun 30, 2022 | 8.72% |
| Mar 31, 2022 | -8.01% |
| Dec 31, 2021 | -4.36% |
| Sep 30, 2021 | 18.96% |
| Jun 30, 2021 | -22.54% |